

# Eugene Braunwald

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4058237/publications.pdf>

Version: 2024-02-01

401  
papers

74,809  
citations

2091

103  
h-index

597

267  
g-index

406  
all docs

406  
docs citations

406  
times ranked

42094  
citing authors

#	ARTICLE	IF	CITATIONS
1	How to live to 100 before developing clinical coronary artery disease: a suggestion. <i>European Heart Journal</i> , 2022, 43, 249-250.	1.0	20
2	Plasma ceramide and phospholipid-based risk score and the risk of cardiovascular death in patients after acute coronary syndrome. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 895-902.	0.8	18
3	SGLT2 inhibitors: the statins of the 21st century. <i>European Heart Journal</i> , 2022, 43, 1029-1030.	1.0	45
4	Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction. <i>JAMA Cardiology</i> , 2022, 7, 17.	3.0	77
5	Impact of Sacubitril/Valsartan Versus Ramipril on Total Heart Failure Events in the PARADISE-MI Trial. <i>Circulation</i> , 2022, 145, 87-89.	1.6	28
6	Association of Apolipoprotein Bâ€‘Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis. <i>JAMA Cardiology</i> , 2022, 7, 250.	3.0	108
7	Edoxaban versus Warfarin in high-risk patients with atrial fibrillation: A comprehensive analysis of high-risk subgroups. <i>American Heart Journal</i> , 2022, 247, 24-32.	1.2	6
8	Heart failure: a 70 year Odyssey. <i>European Heart Journal</i> , 2022, 43, 1697-1699.	1.0	3
9	Cardiovascular Events and Longâ€‘Term Risk of Sudden Death Among Stabilized Patients After Acute Coronary Syndrome: Insights From IMPROVEâ€‘IT. <i>Journal of the American Heart Association</i> , 2022, 11, e022733.	1.6	4
10	Changing the Trajectory of Heart Failure and Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, , CJN.00470122.	2.2	2
11	Ischaemic and bleeding risk in atrial fibrillation with and without peripheral artery disease and efficacy and safety of full- and half-dose edoxaban vs. warfarin: insights from ENGAGE AF-TIMI 48. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 695-706.	1.4	5
12	Cardiac cell therapy: a call for action. <i>European Heart Journal</i> , 2022, 43, 2352-2353.	1.0	8
13	Could Nephilysin Be Already Inhibited by BNP in the LIFE Trial?â€‘Reply. <i>JAMA Cardiology</i> , 2022, , .	3.0	0
14	Gliflozins in the Management of Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2022, 386, 2024-2034.	13.9	113
15	Patients with diabetes mellitus and atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants: meta-analysis of eight outcomes in 58â€‘634 patients across four randomized controlled trials. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, f40-f49.	1.4	13
16	Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients With Cardiometabolic Disease. <i>Circulation</i> , 2021, 143, 470-478.	1.6	32
17	Edoxaban versus Warfarin in Patients with Atrial Fibrillation at the Extremes of Body Weight: An Analysis from the ENGAGE AF-TIMI 48 Trial. <i>Thrombosis and Haemostasis</i> , 2021, 121, 140-149.	1.8	22
18	Sex, Permanent Drug Discontinuation, and Study Retention in Clinical Trials. <i>Circulation</i> , 2021, 143, 685-695.	1.6	22

#	ARTICLE	IF	CITATIONS
19	Genetic Risk Score to Identify Risk of Venous Thromboembolism in Patients With Cardiometabolic Disease. <i>Circulation Genomic and Precision Medicine</i> , 2021, 14, e003006.	1.6	6
20	Efficacy and Safety of Sacubitril/Valsartan in High-Risk Patients in the PIONEER-HF Trial. <i>Circulation: Heart Failure</i> , 2021, 14, e007034.	1.6	27
21	Comparison of the Efficacy and Safety Outcomes of Edoxaban in 8040 Women Versus 13 065 Men With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial. <i>Circulation</i> , 2021, 143, 673-684.	1.6	10
22	Predictors, Type, and Impact of Bleeding on the Net Clinical Benefit of Long-Term Ticagrelor in Stable Patients With Prior Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2021, 10, e017008.	1.6	17
23	Cardiology in 2021. <i>European Heart Journal</i> , 2021, 42, 959-959.	1.0	5
24	Serial assessment of biomarkers and the risk of stroke or systemic embolism and bleeding in patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial. <i>European Heart Journal</i> , 2021, 42, 1698-1706.	1.0	27
25	The path to universality. <i>European Journal of Heart Failure</i> , 2021, 23, 381-383.	2.9	2
26	The Birth of Cardiology: The Golden Decade. <i>European Heart Journal</i> , 2021, 42, 1650-1651.	1.0	2
27	Randomized, Double-Blind Comparison of Half-Dose Versus Full-Dose Edoxaban in 14,014 Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1197-1207.	1.2	29
28	Prospective ARNI vs. ACE inhibitor trial to Determine Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): design and baseline characteristics. <i>European Journal of Heart Failure</i> , 2021, 23, 1040-1048.	2.9	70
29	Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation with warfarin or edoxaban: An in-depth analysis from the ENGAGE AF-TIMI 48 randomized trial. <i>Journal of Clinical Neuroscience</i> , 2021, 86, 294-300.	0.8	5
30	Transseptal left heart catheterization: birth, death, and resurrection. <i>European Heart Journal</i> , 2021, 42, 2327-2328.	1.0	0
31	The war on heart failure. <i>European Journal of Heart Failure</i> , 2021, 23, 915-916.	2.9	2
32	Reflections on Hypertrophic Cardiomyopathy. <i>European Heart Journal</i> , 2021, 42, 2969-2970.	1.0	3
33	Thrombolysis In Myocardial Infarction (TIMI) Study Group. <i>Journal of the American College of Cardiology</i> , 2021, 77, 2822-2845.	1.2	23
34	Cholesterol: the race to the bottom. <i>European Heart Journal</i> , 2021, 42, 4612-4613.	1.0	10
35	A new initiative of the European Heart Journal: the Desmond Julian Award. <i>European Heart Journal</i> , 2021, 42, 3894-3895.	1.0	1
36	Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trial. <i>Nature Medicine</i> , 2021, 27, 1818-1824.	15.2	51

#	ARTICLE	IF	CITATIONS
37	Long-term Ticagrelor in Patients With Prior Coronary Stenting in the PEGASUS-TIMI 54 Trial. <i>Journal of the American Heart Association</i> , 2021, 10, e020446.	1.6	7
38	A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes. <i>Diabetes Care</i> , 2021, 44, 2573-2581.	4.3	13
39	Heart failure with preserved ejection fraction: a stepchild no more!. <i>European Heart Journal</i> , 2021, 42, 3900-3901.	1.0	13
40	A tribute to Attilio Maseri. <i>European Heart Journal</i> , 2021, 42, 4410-4412.	1.0	3
41	Baseline Low-Density Lipoprotein Cholesterol and Clinical Outcomes of Combining Ezetimibe With Statin Therapy in IMPROVE-IT. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1499-1507.	1.2	22
42	Diastolic Dysfunction in Patients With Human Immunodeficiency Virus Receiving Antiretroviral Therapy: Results From the CHART Study. <i>Journal of Cardiac Failure</i> , 2020, 26, 371-380.	0.7	25
43	Atrial Failure as a Clinical Entity. <i>Journal of the American College of Cardiology</i> , 2020, 75, 222-232.	1.2	174
44	Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54. <i>European Heart Journal</i> , 2020, 41, 1625-1632.	1.0	27
45	Relation of White Blood Cell Count to Bleeding and Ischemic Events in Patients With Acute Coronary Syndrome (from the ATLAS ACS 2-TIMI 51 Trial). <i>American Journal of Cardiology</i> , 2020, 125, 661-669.	0.7	7
46	Initiation of Angiotensin-Nepriylsin Inhibition After Acute Decompensated Heart Failure. <i>JAMA Cardiology</i> , 2020, 5, 202.	3.0	57
47	Angiotensin Receptor-Nepriylsin Inhibition Based on History of Heart Failure and Use of Renin-Angiotensin System Antagonists. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1034-1048.	1.2	32
48	Angiotensin-Nepriylsin Inhibition in Black Americans. <i>JACC: Heart Failure</i> , 2020, 8, 859-866.	1.9	11
49	Efficacy and Safety of Sacubitril/Valsartan by Dose Level Achieved in the PIONEER-HF Trial. <i>JACC: Heart Failure</i> , 2020, 8, 834-843.	1.9	19
50	Clinical Application of High-Sensitivity Troponin Testing in the Atherosclerotic Cardiovascular Disease Framework of the Current Cholesterol Guidelines. <i>JAMA Cardiology</i> , 2020, 5, 1255.	3.0	27
51	Cost-effectiveness of Sacubitril-Valsartan in Hospitalized Patients Who Have Heart Failure With Reduced Ejection Fraction. <i>JAMA Cardiology</i> , 2020, 5, 1236.	3.0	46
52	Cardiovascular- and Bleeding-Related Hospitalization Rates With Edoxaban Versus Warfarin in Patients With Atrial Fibrillation Based on Results of the ENGAGE AF-TIMI 48 Trial. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020, 13, e006511.	0.9	6
53	Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials. <i>Lancet, The</i> , 2020, 396, 1637-1643.	6.3	167
54	Prospective Evaluation of Malignancy in 17,708 Patients Randomized to Ezetimibe Versus Placebo. <i>JACC: CardioOncology</i> , 2020, 2, 385-396.	1.7	7

#	ARTICLE	IF	CITATIONS
55	Coexistence and outcome of coronary artery disease in Takotsubo syndrome. <i>European Heart Journal</i> , 2020, 41, 3255-3268.	1.0	49
56	Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2020, 8, 789-799.	1.9	39
57	Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2020, 41, 2109-2117.	1.0	65
58	Nonculprit Lesion Myocardial Infarction Following Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1095-1106.	1.2	25
59	Managing Stable Ischemic Heart Disease. <i>New England Journal of Medicine</i> , 2020, 382, 1468-1470.	13.9	36
60	Association of Hypertrophic Obstructive Cardiomyopathy With Outcomes Following Transcatheter Aortic Valve Replacement. <i>JAMA Network Open</i> , 2020, 3, e1921669.	2.8	14
61	Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter Inhibitors. <i>Journal of the American College of Cardiology</i> , 2020, 75, 422-434.	1.2	302
62	Clinical Benefit of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors. <i>Journal of the American College of Cardiology</i> , 2020, 75, 435-447.	1.2	65
63	Efficacy and safety of edoxaban in patients with diabetes mellitus in the ENGAGE AF-TIMI 48 trial. <i>International Journal of Cardiology</i> , 2020, 304, 185-191.	0.8	25
64	Edoxaban in atrial fibrillation patients with established coronary artery disease: Insights from ENGAGE AF-TIMI 48. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019, 8, 176-185.	0.4	18
65	Treatment of Heart Failure with Sodium-Glucose Cotransporter 2 Inhibitors and Other Anti-diabetic Drugs. <i>Cardiac Failure Review</i> , 2019, 5, 27-30.	1.2	7
66	Edoxaban Versus Warfarin Stratified by Average Blood Pressure in 19 679 Patients With Atrial Fibrillation and a History of Hypertension in the ENGAGE AF-TIMI 48 Trial. <i>Hypertension</i> , 2019, 74, 597-605.	1.3	16
67	Effect of Simvastatin-Ezetimibe Compared With Simvastatin Monotherapy After Acute Coronary Syndrome Among Patients 75 Years or Older. <i>JAMA Cardiology</i> , 2019, 4, 846.	3.0	81
68	The DAPA-HF Trial: A Momentous Victory in the War against Heart Failure. <i>Cell Metabolism</i> , 2019, 30, 847-849.	7.2	39
69	Comparison of Events Across Bleeding Scales in the ENGAGE AF-TIMI 48 Trial. <i>Circulation</i> , 2019, 140, 1792-1801.	1.6	22
70	Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus. <i>Circulation</i> , 2019, 140, 1569-1577.	1.6	94
71	In Memoriam—John Ross Jr, MD. <i>JAMA Cardiology</i> , 2019, 4, 967.	3.0	1
72	Diabetes, heart failure, and renal dysfunction: The vicious circles. <i>Progress in Cardiovascular Diseases</i> , 2019, 62, 298-302.	1.6	151

#	ARTICLE	IF	CITATIONS
73	Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019, 5, 200-206.	1.4	25
74	The Evidence Supporting Cardiovascular Guidelines. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 1053.	3.8	11
75	Clinical Outcomes in Patients With Acute Decompensated Heart Failure Randomly Assigned to Sacubitril/Valsartan or Enalapril in the PIONEER-HF Trial. <i>Circulation</i> , 2019, 139, 2285-2288.	1.6	129
76	Left atrial structure and function and the risk of death or heart failure in atrial fibrillation. <i>European Journal of Heart Failure</i> , 2019, 21, 1571-1579.	2.9	44
77	Outcomes of Women Compared With Men After Non- $\sigma$ ST-Segment Elevation Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2019, 74, 3013-3022.	1.2	54
78	Baseline Characteristics of the VANISH Cohort. <i>Circulation: Heart Failure</i> , 2019, 12, e006231.	1.6	10
79	Clinical outcomes, edoxaban concentration, and anti-factor Xa activity of Asian patients with atrial fibrillation compared with non-Asians in the ENGAGE AF-TIMI 48 trial. <i>European Heart Journal</i> , 2019, 40, 1518-1527.	1.0	67
80	Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure. <i>New England Journal of Medicine</i> , 2019, 380, 539-548.	13.9	848
81	Performance of the ABC Scores for Assessing the Risk of Stroke or Systemic Embolism and Bleeding in Patients With Atrial Fibrillation in ENGAGE AF-TIMI 48. <i>Circulation</i> , 2019, 139, 760-771.	1.6	99
82	Edoxaban and implantable cardiac device interventions: insights from the ENGAGE AF-TIMI 48 trial. <i>Europace</i> , 2019, 21, 306-312.	0.7	6
83	Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial. <i>European Heart Journal</i> , 2019, 40, 1541-1550.	1.0	88
84	Medication Discontinuation in the IMPROVE-IT Trial. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e005041.	0.9	23
85	Prevalence and Outcomes of Polyvascular (Coronary, Peripheral, or Cerebrovascular) Disease in Patients With Diabetes Mellitus (From the SAVOR-TIMI 53 Trial). <i>American Journal of Cardiology</i> , 2019, 123, 145-152.	0.7	25
86	Safety and efficacy of rivaroxaban for the secondary prevention following acute coronary syndromes among biomarker-positive patients: Insights from the ATLAS ACS 2-TIMI 51 trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019, 8, 186-193.	0.4	12
87	Diastolic Dysfunction in Individuals With Human Immunodeficiency Virus Infection: Literature Review, Rationale and Design of the Characterizing Heart Function on Antiretroviral Therapy (CHART) Study. <i>Journal of Cardiac Failure</i> , 2018, 24, 255-265.	0.7	32
88	Andr� Cournand, Bellevue's Cardiopulmonary Laboratory, and Research on Heart Failure. <i>Annals of the American Thoracic Society</i> , 2018, 15, S12-S14.	1.5	0
89	Association of Fibroblast Growth Factor 23 With Recurrent Cardiovascular Events in Patients After an Acute Coronary Syndrome. <i>JAMA Cardiology</i> , 2018, 3, 473.	3.0	33
90	Aortic Stenosis. <i>Circulation</i> , 2018, 137, 2099-2100.	1.6	40

#	ARTICLE	IF	CITATIONS
91	Ticagrelor for Secondary Prevention of Atherothrombotic Events in Patients With Multivessel Coronary Disease. <i>Journal of the American College of Cardiology</i> , 2018, 71, 489-496.	1.2	56
92	Clinical events after interruption of anticoagulation in patients with atrial fibrillation: An analysis from the ENGAGE AF-TIMI 48 trial. <i>International Journal of Cardiology</i> , 2018, 257, 102-107.	0.8	18
93	Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus. <i>Circulation</i> , 2018, 137, 1571-1582.	1.6	304
94	Rationale and design of the comparison of sacubitril/valsartan versus Enalapril on Effect on natriuretic peptide (NT-pro-BNP) in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial. <i>American Heart Journal</i> , 2018, 198, 145-151.	1.2	60
95	Peri-operative Adverse Outcomes in Patients with Atrial Fibrillation Taking Warfarin or Edoxaban: Analysis of the ENGAGE AF-TIMI 48 Trial. <i>Thrombosis and Haemostasis</i> , 2018, 118, 1001-1008.	1.8	18
96	Metabolic syndrome and the risk of adverse cardiovascular events after an acute coronary syndrome. <i>European Journal of Preventive Cardiology</i> , 2018, 25, 830-838.	0.8	20
97	Frequency, Predictors, and Impact of Combined Antiplatelet Therapy on Venous Thromboembolism in Patients With Symptomatic Atherosclerosis. <i>Circulation</i> , 2018, 137, 684-692.	1.6	22
98	Effect of Inorganic Nitrite vs Placebo on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 1764.	3.8	187
99	Treatment of Hypertension. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 1751.	3.8	30
100	Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUS-TIMI 54. <i>Journal of the American Heart Association</i> , 2018, 7, e009260.	1.6	8
101	Usefulness of Rivaroxaban for Secondary Prevention of Acute Coronary Syndrome in Patients With History of Congestive Heart Failure (from the ATLAS-ACS-2 TIMI-51 Trial). <i>American Journal of Cardiology</i> , 2018, 122, 1896-1901.	0.7	17
102	Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 934-943.	5.5	96
103	Edoxaban Versus Warfarin in Latin American Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2018, 72, 1466-1475.	1.2	10
104	Modes and timing of death in 252 patients with non-ST-segment elevation acute coronary syndromes enrolled in 14 TIMI trials. <i>European Heart Journal</i> , 2018, 39, 3810-3820.	1.0	28
105	Fatal or Irreversible Bleeding and Ischemic Events With Rivaroxaban in Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2018, 72, 129-136.	1.2	12
106	Linking Endogenous Factor Xa Activity, a Biologically Relevant Pharmacodynamic Marker, to Edoxaban Plasma Concentrations and Clinical Outcomes in the ENGAGE AF-TIMI 48 Trial. <i>Circulation</i> , 2018, 138, 1963-1973.	1.6	32
107	Cardiac and Renal Effects of Sodium-Glucose Co-Transporter 2 Inhibitors in Diabetes. <i>Journal of the American College of Cardiology</i> , 2018, 72, 1845-1855.	1.2	190
108	Natural History of Patients Postacute Coronary Syndrome Based on Heart Failure Status. <i>American Journal of Cardiology</i> , 2018, 122, 1451-1458.	0.7	2

#	ARTICLE	IF	CITATIONS
109	Cell-Based Therapy in Cardiac Regeneration. <i>Circulation Research</i> , 2018, 123, 132-137.	2.0	67
110	Prognostic and Practical Validation of Current Definitions of Myocardial Infarction Associated With Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 856-864.	1.1	25
111	Gastrointestinal Bleeding With Edoxaban Versus Warfarin. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e003998.	0.9	33
112	D-Dimer Levels and Effect of Rivaroxaban on Those Levels and Outcomes in Patients With Acute Coronary Syndrome (An ATLAS ACS-TIMI 46 Trial Substudy). <i>American Journal of Cardiology</i> , 2018, 122, 1459-1464.	0.7	21
113	Response by Bohula et al to Letters Regarding Article, "Prevention of Stroke With the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved) Tj ETQq1 1 0.784314 rgBTd/Overlo		
114	Vorapaxar in patients with coronary artery bypass grafting: Findings from the TRA 2 <sup>Â</sup> P-TIMI 50 trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2017, 6, 164-172.	0.4	8
115	A novel risk prediction score in atrial fibrillation for a net clinical outcome from the ENGAGE AF-TIMI 48 randomized clinical trial. <i>European Heart Journal</i> , 2017, 38, ehw565.	1.0	37
116	Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2017, 10, .	2.1	139
117	Predictors of Nonuse of a High-Potency Statin After an Acute Coronary Syndrome: Insights From the Stabilization of Plaques Using Darapladib Thrombolysis in Myocardial Infarction 52 (SOLID <sup>Â</sup> TIMI 52) Trial. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	8
118	Atherothrombotic Risk Stratification and Ezetimibe for Secondary Prevention. <i>Journal of the American College of Cardiology</i> , 2017, 69, 911-921.	1.2	157
119	The Design of the Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Trial. <i>American Heart Journal</i> , 2017, 187, 145-155.	1.2	41
120	Soluble ST2 in Heart Failure With Preserved Ejection Fraction. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	64
121	Effect of Oral Iron Repletion on Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction and Iron Deficiency. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 1958.	3.8	329
122	Impact of Ezetimibe on the Rate of Cardiovascular-Related Hospitalizations and Associated Costs Among Patients With a Recent Acute Coronary Syndrome. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2017, 10, .	0.9	8
123	INDIE-HFpEF (Inorganic Nitrite Delivery to Improve Exercise Capacity in Heart Failure With Preserved) Tj ETQq1 1 0.784314 rgBT /Overlo	1.6	47
124	Accelerometer-Measured Daily Activity in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2017, 10, e003878.	1.6	45
125	Valvular Heart Disease Patients on Edoxaban or Warfarin in the ENGAGE <sup>Â</sup> AF-TIMI 48 Trial. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1372-1382.	1.2	111
126	Long-term Safety and Efficacy of Achieving Very Low Levels of Low-Density Lipoprotein Cholesterol. <i>JAMA Cardiology</i> , 2017, 2, 547.	3.0	144



#	ARTICLE	IF	CITATIONS
127	Microangiopathy, Arterial Stiffness, and Risk Stratification in Patients With Type 2 Diabetes—Reply. <i>JAMA Cardiology</i> , 2017, 2, 821.	3.0	0
128	Potent P2Y <sub>12</sub> Inhibitors in Men Versus Women. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1549-1559.	1.2	51
129	High-Sensitivity Troponin I in Stable Patients with Atherosclerotic Disease in the TRA 2 <sup>o</sup> P - TIMI 50 Trial. <i>Clinical Chemistry</i> , 2017, 63, 307-315.	1.5	19
130	Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International) Trial. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1549-1559.	1.2	51
131	An Important Step for Thrombocardiology. <i>New England Journal of Medicine</i> , 2017, 377, 1387-1388.	13.9	18
132	Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease. <i>New England Journal of Medicine</i> , 2017, 377, 1217-1227.	13.9	780
133	Cardiomyopathies. <i>Circulation Research</i> , 2017, 121, 711-721.	2.0	106
134	Hypertrophic Cardiomyopathy. <i>Circulation Research</i> , 2017, 121, 749-770.	2.0	790
135	Efficacy and Safety of Ticagrelor Over Time in Patients With Prior MI in PEGASUS-TIMI 54. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1368-1375.	1.2	74
136	Achieving Extended Longevity and Quality of Life for Senior Patients With Hypertrophic Cardiomyopathy: What Is Possible. <i>American Journal of Medicine</i> , 2017, 130, 1236-1237.	0.6	2
137	Efficacy and Safety of Spironolactone in Acute Heart Failure. <i>JAMA Cardiology</i> , 2017, 2, 950.	3.0	199
138	Digoxin Use and Subsequent Clinical Outcomes in Patients With Atrial Fibrillation With or Without Heart Failure in the ENGAGE AF-TIMI 48 Trial. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	30
139	Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial. <i>Diabetes Care</i> , 2017, 40, 69-76.	4.3	205
140	Nonobstructive Hypertrophic Cardiomyopathy Out of the Shadows: Known from the Beginning but Largely Ignored Until Now. <i>American Journal of Medicine</i> , 2017, 130, 119-123.	0.6	17
141	Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials. <i>European Heart Journal</i> , 2016, 37, ehv443.	1.0	293
142	Prevalence, Profile, and Prognosis of Severe Obesity in Contemporary Hospitalized Heart Failure Trial Populations. <i>JACC: Heart Failure</i> , 2016, 4, 923-931.	1.9	40
143	Sudden Cardiac Death in Patients With Atrial Fibrillation: Insights From the ENGAGE AF-TIMI 48 Trial. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	53
144	Response to Letter Regarding Article, "Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT." <i>Circulation</i> , 2016, 133, e463.	1.6	0

#	ARTICLE	IF	CITATIONS
145	Predisposing Factors for Any and Major Hypoglycemia With Saxagliptin Versus Placebo and Overall: Analysis From the SAVOR-TIMI 53 Trial. <i>Diabetes Care</i> , 2016, 39, 1329-1337.	4.3	12
146	Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	215
147	Intravenous Beta-Blockade for Limiting Myocardial Infarct Size. <i>Journal of the American College of Cardiology</i> , 2016, 67, 2105-2107.	1.2	3
148	Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease. <i>Journal of the American College of Cardiology</i> , 2016, 67, 2719-2728.	1.2	303
149	Reduction in Ischemic Events With Ticagrelor in Diabetic Patients With Prior Myocardial Infarction in PEGASUS-TIMI 54. <i>Journal of the American College of Cardiology</i> , 2016, 67, 2732-2740.	1.2	179
150	Oral Iron Therapy for Heart Failure With Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	38
151	The Prognostic Significance of Cardiac Structure and Function in Atrial Fibrillation: The ENGAGE AF-TIMI 48 Echocardiographic Substudy. <i>Journal of the American Society of Echocardiography</i> , 2016, 29, 537-544.	1.2	29
152	Edoxaban Versus Warfarin in Atrial Fibrillation Patients at Risk of Falling. <i>Journal of the American College of Cardiology</i> , 2016, 68, 1169-1178.	1.2	133
153	Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 1289.	3.8	974
154	Cardiovascular Biomarker Score and Clinical Outcomes in Patients With Atrial Fibrillation. <i>JAMA Cardiology</i> , 2016, 1, 999.	3.0	64
155	Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 500.	3.8	457
156	Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events. <i>Stroke</i> , 2016, 47, 2075-2082.	1.0	83
157	Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: insights from ENGAGE AF-TIMI 48. <i>European Journal of Heart Failure</i> , 2016, 18, 1153-1161.	2.9	73
158	Rationale and Design of the ATHENA-HF Trial. <i>JACC: Heart Failure</i> , 2016, 4, 726-735.	1.9	30
159	Universal Classification System Type of Incident Myocardial Infarction in Patients With Stable Atherosclerosis: Observations From Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2-P)-TIMI 50. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	13
160	The benefit of adding ezetimibe to statin therapy in patients with prior coronary artery bypass graft surgery and acute coronary syndrome in the IMPROVE-IT trial. <i>European Heart Journal</i> , 2016, 37, 3576-3584.	1.0	71
161	Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction. <i>Circulation</i> , 2016, 134, 861-871.	1.6	40
162	Concomitant Use of Single Antiplatelet Therapy With Edoxaban or Warfarin in Patients With Atrial Fibrillation: Analysis From the ENGAGE AF-TIMI48 Trial. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	93

#	ARTICLE	IF	CITATIONS
163	Atherothrombotic Risk Stratification and the Efficacy and Safety of Vorapaxar in Patients With Stable Ischemic Heart Disease and Previous Myocardial Infarction. <i>Circulation</i> , 2016, 134, 304-313.	1.6	143
164	Updates on Acute Coronary Syndrome. <i>JAMA Cardiology</i> , 2016, 1, 718.	3.0	127
165	Circulation : The Beat Goes On. <i>Circulation</i> , 2016, 134, 6-8.	1.6	6
166	Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial. <i>Circulation</i> , 2016, 134, 24-36.	1.6	234
167	Treatment of Left Main Coronary Artery Disease. <i>New England Journal of Medicine</i> , 2016, 375, 2284-2285.	13.9	16
168	Long-term Tolerability of Ticagrelor for the Secondary Prevention of Major Adverse Cardiovascular Events. <i>JAMA Cardiology</i> , 2016, 1, 425.	3.0	88
169	Mortality in Patients with Atrial Fibrillation Randomized to Edoxaban or Warfarin: Insights from the ENGAGE AF-TIMI 48 Trial. <i>American Journal of Medicine</i> , 2016, 129, 850-857.e2.	0.6	58
170	Reduction of LDL-cholesterol: important at all ages. <i>European Heart Journal</i> , 2016, 37, 1982-1984.	1.0	5
171	Outcomes in Stable Patients With Previous Atherothrombotic Events Receiving Vorapaxar Who Experience a New Acute Coronary Event (from TRA2°P-TIMI 50). <i>American Journal of Cardiology</i> , 2016, 117, 1055-1058.	0.7	5
172	Treatment of Heart Failure With Preserved Ejection Fraction. <i>JAMA Cardiology</i> , 2016, 1, 7.	3.0	35
173	Academic-industrial collaboration in the development of the first angiotensin receptor blocker: neprilysin inhibitor in the treatment of heart failure: Table A1. <i>European Heart Journal</i> , 2016, 37, 745-746.	1.0	4
174	Platelet Inhibition With Ticagrelor 60 mg Versus 90 mg Twice Daily in the PEGASUS-TIMI 54 Trial. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1145-1154.	1.2	108
175	Edoxaban vs warfarin in patients with nonvalvular atrial fibrillation in the US Food and Drug Administration approval population: An analysis from the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) trial. <i>American Heart Journal</i> . 2016. 172. 144-151.	1.2	13
176	Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y <sub>12</sub> inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54. <i>European Heart Journal</i> , 2016, 37, 1133-1142.	1.0	138
177	Cardiovascular Outcomes of Patients in SAVOR-TIMI 53 by Baseline Hemoglobin A1c. <i>American Journal of Medicine</i> , 2016, 129, 340.e1-340.e8.	0.6	34
178	Another step toward personalized care of patients with heart failure. <i>European Journal of Heart Failure</i> , 2015, 17, 988-990.	2.9	11
179	Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , 2015, 372, 2387-2397.	13.9	3,337
180	Edoxaban vs. warfarin in vitamin K antagonist experienced and naive patients with atrial fibrillation. <i>European Heart Journal</i> , 2015, 36, 1470-1477.	1.0	47

#	ARTICLE	IF	CITATIONS
181	Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. <i>Lancet, The</i> , 2015, 385, 2288-2295.	6.3	335
182	Cardiovascular pharmacology: a look back and a glimpse into the future. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2015, 1, 7-9.	1.4	5
183	Decongestion Strategies and Renin-Angiotensin-Aldosterone System Activation in Acute Heart Failure. <i>JACC: Heart Failure</i> , 2015, 3, 97-107.	1.9	95
184	Prognostic performance of a high-sensitivity assay for cardiac troponin I after non-ST elevation acute coronary syndrome: Analysis from MERLIN-TIMI 36. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2015, 4, 431-440.	0.4	17
185	Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial. <i>Lancet, The</i> , 2015, 385, 2280-2287.	6.3	153
186	The Path to an Angiotensin Receptor Antagonist-Nephrilysin Inhibitor in the Treatment of Heart Failure. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1029-1041.	1.2	133
187	Progress in the Noninvasive Detection of High-Risk Coronary Plaques. <i>Journal of the American College of Cardiology</i> , 2015, 66, 347-349.	1.2	8
188	Effect of ranolazine on atrial fibrillation in patients with non-ST elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 trial. <i>Europace</i> , 2015, 17, 32-37.	0.7	46
189	Galectin-3 in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2015, 3, 245-252.	1.9	49
190	Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction. <i>New England Journal of Medicine</i> , 2015, 372, 1791-1800.	13.9	1,585
191	Efficacy and Safety of Saxagliptin in Older Participants in the SAVOR-TIMI 53 Trial. <i>Diabetes Care</i> , 2015, 38, 1145-1153.	4.3	73
192	Response to Letter Regarding Article, "Heart Failure, Saxagliptin and Diabetes Mellitus: Observations From the SAVOR-TIMI 53 Randomized Trial". <i>Circulation</i> , 2015, 132, e121-2.	1.6	61
193	Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT. <i>Circulation</i> , 2015, 132, 1224-1233.	1.6	267
194	Causes of late mortality with dual antiplatelet therapy after coronary stents. <i>European Heart Journal</i> , 2015, 37, ehv614.	1.0	38
195	Efficacy and Safety of Vorapaxar With and Without a Thienopyridine for Secondary Prevention in Patients With Previous Myocardial Infarction and No History of Stroke or Transient Ischemic Attack. <i>Circulation</i> , 2015, 132, 1871-1879.	1.6	39
196	The war against heart failure: the Lancet lecture. <i>Lancet, The</i> , 2015, 385, 812-824.	6.3	646
197	Left atrial structure and function in atrial fibrillation: ENGAGE AF-TIMI 48. <i>European Heart Journal</i> , 2014, 35, 1457-1465.	1.0	174
198	Coronary Stent Thrombosis With Vorapaxar Versus Placebo. <i>Journal of the American College of Cardiology</i> , 2014, 64, 2309-2317.	1.2	41

#	ARTICLE	IF	CITATIONS
199	Effect of Darapladib on Major Coronary Events After an Acute Coronary Syndrome. JAMA - Journal of the American Medical Association, 2014, 312, 1006.	3.8	375
200	Recognizing Worsening Chronic Heart Failure as an Entity and an End Point in Clinical Trials. JAMA - Journal of the American Medical Association, 2014, 312, 789.	3.8	58
201	Cerebrovascular Events in 21 105 Patients With Atrial Fibrillation Randomized to Edoxaban Versus Warfarin. Stroke, 2014, 45, 2372-2378.	1.0	46
202	GLP-1 Agonist Therapy for Advanced Heart Failure With Reduced Ejection Fraction. Circulation: Heart Failure, 2014, 7, 673-679.	1.6	41
203	Responsiveness to loop diuretics in heart failure. European Heart Journal, 2014, 35, 1235-1237.	1.0	14
204	Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin—Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial. American Heart Journal, 2014, 167, 437-444.e5.	1.2	89
205	Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet, The, 2014, 383, 955-962.	6.3	3,942
206	The Year in Acute Coronary Syndrome. Journal of the American College of Cardiology, 2014, 63, 201-214.	1.2	14
207	Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents. New England Journal of Medicine, 2014, 371, 2155-2166.	13.9	1,645
208	Prasugrel Versus Clopidogrel in Patients With ST-Segment Elevation Myocardial Infarction According to Timing of Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2014, 7, 604-612.	1.1	45
209	Fondation Leducq. Circulation Research, 2014, 115, 419-422.	2.0	2
210	Transition of Patients From Blinded Study—Drug to Open-Label Anticoagulation. Journal of the American College of Cardiology, 2014, 64, 576-584.	1.2	39
211	Resting Ventricular—Vascular Function and Exercise Capacity in Heart Failure With Preserved Ejection Fraction. Circulation: Heart Failure, 2014, 7, 580-589.	1.6	40
212	Angiographic Outcomes With Early Eptifibatid Therapy in Non—ST-Segment Elevation Acute Coronary Syndrome (from the EARLY ACS Trial). American Journal of Cardiology, 2014, 113, 1297-1305.	0.7	10
213	Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: Final baseline characteristics of the IMPROVE-IT study population. American Heart Journal, 2014, 168, 205-212.e1.	1.2	93
214	The ten advances that have defined modern cardiology. Trends in Cardiovascular Medicine, 2014, 24, 179-183.	2.3	13
215	Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. New England Journal of Medicine, 2013, 369, 1317-1326.	13.9	3,017
216	Unstable Angina. Circulation, 2013, 127, 2452-2457.	1.6	186

#	ARTICLE	IF	CITATIONS
217	Edoxaban versus Warfarin in Patients with Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2013, 369, 2093-2104.	13.9	4,215
218	Cardiac Troponin After Percutaneous Coronary Intervention and 1-Year Mortality in Non-ST-Segment Elevation Acute Coronary Syndrome Using Systematic Evaluation of Biomarker Trends. <i>Journal of the American College of Cardiology</i> , 2013, 62, 242-251.	1.2	39
219	Research Advances in Heart Failure. <i>Circulation Research</i> , 2013, 113, 633-645.	2.0	59
220	Heart Failure. <i>JACC: Heart Failure</i> , 2013, 1, 1-20.	1.9	612
221	CardioPulse Articles. <i>European Heart Journal</i> , 2013, 34, 943-948.	1.0	1
222	Low-Dose Dopamine or Low-Dose Nesiritide in Acute Heart Failure With Renal Dysfunction. <i>JAMA - Journal of the American Medical Association</i> , 2013, 310, 2533.	3.8	410
223	Burton E. Sobel: 1937-2013. <i>Circulation</i> , 2013, 128, 188-189.	1.6	0
224	Cardiovascular science: opportunities for translating research into improved care. <i>Journal of Clinical Investigation</i> , 2013, 123, 6-10.	3.9	26
225	The rise of cardiovascular medicine. <i>European Heart Journal</i> , 2012, 33, 838-845.	1.0	59
226	Hypertrophic cardiomyopathy: The first century 1869-1969. <i>Global Cardiology Science &amp; Practice</i> , 2012, 2012, 5.	0.3	6
227	The Thrombolysis in Myocardial Infarction (TIMI) Study Group experience. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2012, 144, 762-770.	0.4	14
228	The treatment of acute myocardial infarction: the Past, the Present, and the Future. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2012, 1, 9-12.	0.4	55
229	Unstable Angina and Non-ST Elevation Myocardial Infarction. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 185, 924-932.	2.5	66
230	Rivaroxaban in Patients with a Recent Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , 2012, 366, 9-19.	13.9	1,681
231	Vorapaxar in the Secondary Prevention of Atherothrombotic Events. <i>New England Journal of Medicine</i> , 2012, 366, 1404-1413.	13.9	841
232	The Year in Non-ST-Segment Elevation Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2011, 58, 2342-2354.	1.2	7
233	Study design and rationale for the Stabilization of pLaques using Darapladib Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome. <i>American Heart Journal</i> , 2011, 162, 613-619.e1.	1.2	77
234	Clinical Efforts to Reduce Myocardial Infarct Size - The Next Step. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2011, 16, 349-353.	1.0	19

#	ARTICLE	IF	CITATIONS
235	HMG CoA Reduction in Patients with Average Cholesterol Concentrations. <i>Clinical Chemistry</i> , 2011, 57, 1072-1073.	1.5	2
236	Response to Letter Regarding Article, "Cost-Effectiveness of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndromes and Planned Percutaneous Coronary Intervention: Results From the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38". <i>Circulation</i> , 2010, 122, .	1.6	1
237	Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective Anticoagulation with factor xA next Generation in Atrial Fibrillation "Thrombolysis in Myocardial Infarction study 48 (ENGAGE AF"TIMI 48). <i>American Heart Journal</i> . 2010. 160. 635-641.e2.	1.2	439
238	Adventures in Cardiovascular Research. <i>Circulation</i> , 2009, 120, 170-180.	1.6	22
239	Hypertrophic Cardiomyopathy: The Early Years. <i>Journal of Cardiovascular Translational Research</i> , 2009, 2, 341-348.	1.1	15
240	Preface. <i>Heart Failure Clinics</i> , 2009, 5, xiii-xiv.	1.0	11
241	Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. <i>Lancet</i> , The, 2009, 374, 989-997.	6.3	650
242	JACC: Cardiovascular Interventions: The End of the Beginning. <i>JACC: Cardiovascular Interventions</i> , 2008, 1, 1-2.	1.1	24
243	Clinical Considerations with the Use of Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention. <i>Clinical Cardiology</i> , 2008, 31, I28-I35.	0.7	2
244	Investigating the Mechanisms of Hyporesponse to Antiplatelet Approaches. <i>Clinical Cardiology</i> , 2008, 31, I21-I27.	0.7	7
245	Assessing the Current Role of Platelet Function Testing. <i>Clinical Cardiology</i> , 2008, 31, I10-I16.	0.7	26
246	Antiplatelet Strategies: Evaluating Their Current Role in the Setting of Acute Coronary Syndromes. <i>Clinical Cardiology</i> , 2008, 31, I2-I9.	0.7	9
247	The Problem of Persistent Platelet Activation in Acute Coronary Syndromes and Following Percutaneous Coronary Intervention. <i>Clinical Cardiology</i> , 2008, 31, I17-I20.	0.7	33
248	Antiplatelet Therapy and Platelet Function Testing. <i>Clinical Cardiology</i> , 2008, 31, I1-I11.	0.7	2
249	Antiplatelet Therapy and Platelet Function Testing. <i>Clinical Cardiology</i> , 2008, 31, I36-I36.	0.7	7
250	Biomarkers in Heart Failure. <i>New England Journal of Medicine</i> , 2008, 358, 2148-2159.	13.9	1,111
251	The Year in Non"ST-Segment Elevation Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2008, 52, 1095-1103.	1.2	9
252	Summary of Issues Emanating from the Workshop on Congestive Heart Failure. <i>Artificial Organs</i> , 2008, 6, 342-344.	1.0	0

#	ARTICLE	IF	CITATIONS
253	The Management of Heart Failure. <i>Circulation: Heart Failure</i> , 2008, 1, 58-62.	1.6	28
254	The American Society for Clinical Investigation, 1952-1975: a personal perspective. <i>Journal of Clinical Investigation</i> , 2008, 118, 1228-1230.	3.9	2
255	Effects of Ranolazine on Recurrent Cardiovascular Events in Patients With Non-ST-Elevation Acute Coronary Syndromes <SUBTITLE>The MERLIN-TIMI 36 Randomized Trial</SUBTITLE>. <i>JAMA - Journal of the American Medical Association</i> , 2007, 297, 1775.	3.8	448
256	Reducing Myocardial Injury by Minimizing Imbalance between Oxygen Supply and Demand. <i>Anesthesiology</i> , 2007, 107, 161-163.	1.3	1
257	The Year in Non-ST-Segment Elevation Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2007, 50, 1386-1395.	1.2	3
258	Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , 2007, 357, 2001-2015.	13.9	5,933
259	Epilogue: What Do Clinicians Expect From Imagers?. <i>Journal of the American College of Cardiology</i> , 2006, 47, C101-C103.	1.2	74
260	The Year in Non-ST-Segment Elevation Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2006, 48, 386-395.	1.2	5
261	Can Low-Density Lipoprotein Be Too Low? The Safety and Efficacy of Achieving Very Low Low-Density Lipoprotein With Intensive Statin Therapy. <i>Journal of the American College of Cardiology</i> , 2005, 46, 1411-1416.	1.2	306
262	The Year in Non-ST-Segment Elevation Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2005, 46, 906-919.	1.2	40
263	Cardiology: how did we get here, where are we today and where are we going?. <i>Canadian Journal of Cardiology</i> , 2005, 21, 1015-7.	0.8	5
264	Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , 2004, 350, 1495-1504.	13.9	4,527
265	Age and Routine Invasive Management of Acute Coronary Syndromes. <i>Annals of Internal Medicine</i> , 2004, 141, 967.	2.0	0
266	Cardiology: the past, the present, and the future. <i>Journal of the American College of Cardiology</i> , 2003, 42, 2031-2041.	1.2	49
267	Application of Current Guidelines to the Management of Unstable Angina and Non-ST-Elevation Myocardial Infarction. <i>Circulation</i> , 2003, 108, 28III-37.	1.6	52
268	Contemporary Evaluation and Management of Hypertrophic Cardiomyopathy. <i>Circulation</i> , 2002, 106, 1312-1316.	1.6	160
269	Hypertrophic Cardiomyopathy - The Benefits of a Multidisciplinary Approach. <i>New England Journal of Medicine</i> , 2002, 347, 1306-1307.	13.9	12
270	Prognosis in the Thrombolysis in Myocardial Ischemia III Registry according to the Braunwald unstable angina pectoris classification. <i>American Journal of Cardiology</i> , 2002, 90, 821-826.	0.7	19



#	ARTICLE	IF	CITATIONS
271	Changing the practice of cardiovascular medicine. <i>Atherosclerosis Supplements</i> , 2001, 2, 27-30.	1.2	4
272	Impact of contrast agent type (ionic versus nonionic) used for coronary angiography on angiographic, electrocardiographic, and clinical outcomes following thrombolytic administration in acute myocardial infarction. <i>Catheterization and Cardiovascular Interventions</i> , 2001, 53, 6-11.	0.7	8
273	Combination Therapy With Abciximab Reduces Angiographically Evident Thrombus in Acute Myocardial Infarction. <i>Circulation</i> , 2001, 103, 2550-2554.	1.6	440
274	Results of the Treat Angina With Aggrastat and Determine the Cost of Therapy With an Invasive or Conservative Strategy (TACTICS-TIMI 18) Trial: A Comparison of Invasive Versus Conservative Strategy in Patients With Unstable Angina and Non- $\sigma$ ST-Segment Elevation Myocardial Infarction. <i>Circulation</i> , 2000, 102, 2672-2672.	1.6	7
275	TIMI Risk Score for ST-Elevation Myocardial Infarction: A Convenient, Bedside, Clinical Score for Risk Assessment at Presentation. <i>Circulation</i> , 2000, 102, 2031-2037.	1.6	1,302
276	A Classification of Unstable Angina Revisited. <i>Circulation</i> , 2000, 102, 118-122.	1.6	348
277	Reexamination of the Thrombin Hypothesis: What We Have Learned from TIMI 9B and GUSTO IIb. <i>Journal of Thrombosis and Thrombolysis</i> , 1997, 4, 321-323.	1.0	0
278	Induced Septal Infarction. <i>Circulation</i> , 1997, 95, 1981-1982.	1.6	34
279	The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels. <i>New England Journal of Medicine</i> , 1996, 335, 1001-1009.	13.9	7,059
280	Time to reperfusion: The critical modulator in thrombolysis and primary angioplasty. <i>Journal of Thrombosis and Thrombolysis</i> , 1996, 3, 117-125.	1.0	32
281	Morning Resistance to Thrombolytic Therapy. <i>Circulation</i> , 1995, 91, 1604-1606.	1.6	41
282	Tissue plasminogen activator and acute pulmonary embolism. <i>Journal of Cellular Biochemistry</i> , 1988, 38, 303-312.	1.2	5
283	Fraud and other matters?. <i>Nature</i> , 1987, 328, 196-196.	13.7	0
284	Effects of Chronic Heart Failure on the Inotropic Response of the Right Ventricle of the Conscious Dog to a Cardiac Glycoside and to Tachycardia. <i>Circulation</i> , 1974, 50, 728-734.	1.6	26
285	Assessment of Left Ventricular Performance in Man. <i>Circulation</i> , 1973, 47, 924-935.	1.6	42
286	Protection of the Ischemic Myocardium. <i>Hospital Practice</i> (1995), 1973, 8, 61-74.	0.5	13
287	Assessment of Cardiac Contractility. <i>Circulation</i> , 1971, 44, 47-58.	1.6	228
288	Effects of hyperlipoproteinemias and their treatment on the peripheral circulation. <i>Journal of Clinical Investigation</i> , 1970, 49, 1007-1015.	3.9	132

#	ARTICLE	IF	CITATIONS
289	Circulatory Effects of Electrical Stimulation of the Carotid Sinus Nerves in Man. <i>Circulation</i> , 1969, 40, 269-276.	1.6	79
290	Partition of Blood Flow to the Cutaneous and Muscular Beds of the Forearm at Rest and during Leg Exercise in Normal Subjects and in Patients with Heart Failure. <i>Circulation Research</i> , 1969, 24, 799-806.	2.0	152
291	Mechanochemistry of Cardiac Muscle. <i>Circulation Research</i> , 1969, 24, 313-320.	2.0	18
292	EFFECTS OF HEART FAILURE, VENTRICULAR HYPERTROPHY, AND ALTERATIONS IN THE THYROID STATE ON THE CONTRACTILITY OF ISOLATED CARDIAC MUSCLE. <i>Annals of the New York Academy of Sciences</i> , 1969, 156, 379-386.	1.8	7
293	Operative Treatment in Idiopathic Hypertrophic Subaortic Stenosis. <i>Circulation</i> , 1968, 37, 589-596.	1.6	127
294	Augmented Sympathetic Neurotransmitter Activity in the Peripheral Vascular Bed of Patients with Congestive Heart Failure and Cardiac Norepinephrine Depletion. <i>Circulation</i> , 1968, 38, 629-634.	1.6	87
295	Contractile State of the Left Ventricle in Man. <i>Circulation Research</i> , 1968, 22, 451-463.	2.0	281
296	Integrity of Energy Stores in Cat Papillary Muscle. <i>Circulation Research</i> , 1968, 22, 213-219.	2.0	24
297	Impaired Rate of Left Ventricular Filling in Idiopathic Hypertrophic Subaortic Stenosis and Valvular Aortic Stenosis. <i>Circulation</i> , 1968, 37, 8-14.	1.6	172
298	Idiopathic Hypertrophic Subaortic Stenosis. <i>Circulation</i> , 1968, 37, 759-788.	1.6	557
299	Effects of Acute Valvular Regurgitation on the Oxygen Consumption of the Canine Heart. <i>Circulation Research</i> , 1968, 23, 33-43.	2.0	45
300	Severe Mitral Regurgitation Following Acute Myocardial Infarction and Ruptured Papillary Muscle. <i>Circulation</i> , 1968, 37, .	1.6	28
301	Chapter 4: Deaths Related to Cardiac Catheterization. <i>Circulation</i> , 1968, 37, .	1.6	13
302	Chapter 17: Transseptal Left Heart Catheterization. <i>Circulation</i> , 1968, 37, .	1.6	7
303	Chapter 18: Percutaneous Left Ventricular Puncture. <i>Circulation</i> , 1968, 37, .	1.6	5
304	Aortic Stenosis. <i>Circulation</i> , 1968, 38, 61-7.	1.6	910
305	Chapter 13: Severe Hypotension. <i>Circulation</i> , 1968, 37, .	1.6	0
306	Characterization of the Circulatory Response to Maximal Upright Exercise in Normal Subjects and Patients with Heart Disease. <i>Circulation</i> , 1967, 35, 1049-1062.	1.6	150

#	ARTICLE	IF	CITATIONS
307	The Effects of Mitral Regurgitation on the Pattern of Instantaneous Aortic Blood Flow Clinical and Experimental Observations. <i>Circulation</i> , 1967, 36, 45-53.	1.6	24
308	Effects of Frequency of Contraction and Ionic Environment on the Responses of Heart Muscle to Acetylcholine. <i>Circulation Research</i> , 1967, 21, 573-582.	2.0	30
309	Significance of an Atrial Gallop Sound in Mitral Regurgitation. <i>Circulation</i> , 1967, 35, 112-118.	1.6	48
310	Interactions between Changes in the Intensity and Duration of the Active State in the Characterization of Inotropic Stimuli on Heart Muscle. <i>Circulation Research</i> , 1967, 21, 857-868.	2.0	46
311	Myocardial High Energy Phosphate Stores in Cardiac Hypertrophy and Heart Failure. <i>Circulation Research</i> , 1967, 21, 365-374.	2.0	124
312	Amelioration of Angina Pectoris in Idiopathic Hypertrophic Subaortic Stenosis with Beta-Adrenergic Blockade. <i>Circulation</i> , 1967, 35, 847-851.	1.6	165
313	Physiological Differences between the Effects of Neuronally Released and Bloodborne Norepinephrine on Beta Adrenergic Receptors in the Arterial Bed of the Dog. <i>Circulation Research</i> , 1967, 21, 217-228.	2.0	65
314	Prosthetic Replacement of the Mitral Valve. <i>Circulation</i> , 1967, 35, 962-979.	1.6	112
315	Contractile State of Cardiac Muscle Obtained from Cats with Experimentally Produced Ventricular Hypertrophy and Heart Failure. <i>Circulation Research</i> , 1967, 21, 341-354.	2.0	518
316	CLINICAL AND HEMODYNAMIC APPRAISAL OF BETA ADRENERGIC BLOCKING DRUGS. <i>Annals of the New York Academy of Sciences</i> , 1967, 139, 952-967.	1.8	26
317	Combined Prosthetic Replacement of the Mitral and Aortic Valves. <i>Circulation</i> , 1967, 35, 115-23.	1.6	12
318	Circulatory Effects of Acute Expansion of Blood Volume:. <i>Circulation Research</i> , 1966, 19, 26-32.	2.0	75
319	The Assessment of Operative Results in Congenital Heart Disease by Intraoperative Indicator-Dilution Curves. <i>Circulation</i> , 1966, 33, 263-269.	1.6	11
320	Effects of Changes in Body Position on the Severity of Obstruction to Left Ventricular Outflow in Idiopathic Hypertrophic Subaortic Stenosis. <i>Circulation</i> , 1966, 33, 374-382.	1.6	26
321	Ligation of the Main Pulmonary Artery and Systemic-Pulmonary Arterial Anastomosis. <i>Circulation</i> , 1966, 34, 55-60.	1.6	3
322	Studies on Digitalis. <i>Circulation</i> , 1966, 34, 532-539.	1.6	116
323	The Mechanism of the Intraventricular Pressure Gradient in Idiopathic Hypertrophic Subaortic Stenosis. <i>Circulation</i> , 1966, 34, 558-578.	1.6	177
324	Left Ventricular Performance During Muscular Exercise in Patients with and without Cardiac Dysfunction. <i>Circulation</i> , 1966, 34, 597-608.	1.6	172

#	ARTICLE	IF	CITATIONS
325	Reduction of the Cardiac Response to Postganglionic Sympathetic Nerve Stimulation in Experimental Heart Failure. <i>Circulation Research</i> , 1966, 19, 51-56.	2.0	126
326	Myocardial High Energy Phosphate Stores in Acutely Induced Hypoxic Heart Failure. <i>Circulation Research</i> , 1966, 19, 221-229.	2.0	83
327	Acute Severe Mitral Regurgitation Secondary to Ruptured Chordae Tendineae. <i>Circulation</i> , 1966, 33, 58-70.	1.6	153
328	Alterations in Regional Pulmonary Blood Flow in Mitral Valve Disease Studied by Radioisotope Scanning. <i>Circulation</i> , 1966, 34, 363-376.	1.6	117
329	Determinants of atrial contractile force in the intact heart. <i>American Journal of Physiology</i> , 1965, 209, 1061-1068.	5.0	108
330	Velocity of contraction as a determinant of myocardial oxygen consumption. <i>American Journal of Physiology</i> , 1965, 209, 919-927.	5.0	331
331	Mechanism of increase of myocardial oxygen uptake produced by catecholamines <sup>1</sup> . <i>American Journal of Physiology</i> , 1965, 209, 913-918.	5.0	86
332	The Incidence and Management of "Medical" Complications Following Cardiac Operations. <i>Circulation</i> , 1965, 32, 608-619.	1.6	52
333	Mechanism of Norepinephrine Depletion in Experimental Heart Failure Produced by Aortic Constriction in the Guinea Pig. <i>Circulation Research</i> , 1965, 17, 312-321.	2.0	147
334	An Intrinsic Adrenergic Vasodilator Mechanism in the Coronary Vascular Bed of the Dog. <i>Circulation Research</i> , 1965, 16, 376-382.	2.0	94
335	The Effects of Nitroglycerin and Amyl Nitrite on Arteriolar and Venous Tone in the Human Forearm. <i>Circulation</i> , 1965, 32, 755-766.	1.6	443
336	A Method for the Detection and Quantification of Impaired Sodium Excretion. <i>Circulation</i> , 1965, 32, 223-231.	1.6	78
337	Effects of Changing Heart Rate in Man by Electrical Stimulation of the Right Atrium. <i>Circulation</i> , 1965, 32, 549-558.	1.6	256
338	Studies on Cardiac Dimensions in Intact Unanesthetized Man. <i>Circulation</i> , 1965, 32, 767-771.	1.6	169
339	Editorial. <i>Circulation</i> , 1965, 32, 677-681.	1.6	25
340	Electroaugmentation of Ventricular Performance and Oxygen Consumption by Repetitive Application of Paired Electrical Stimuli. <i>Circulation Research</i> , 1965, 16, 332-342.	2.0	120
341	Relative Roles of the Sympathetic and Parasympathetic Nervous Systems in the Reflex Control of Heart Rate. <i>Circulation Research</i> , 1965, 16, 363-375.	2.0	250
342	Effects of Aortic Regurgitation on Left Ventricular Performance. <i>Circulation</i> , 1965, 31, .	1.6	12

#	ARTICLE	IF	CITATIONS
343	Circulatory response to hypoxia in unanesthetized dogs with and without cardiac denervation. American Journal of Physiology, 1964, 207, 753-758.	5.0	27
344	Effect of hemorrhagic shock on release of norepinephrine by tyramine. American Journal of Physiology, 1964, 206, 1262-1266.	5.0	6
345	The Circulatory Response of Patients with Idiopathic Hypertrophic Subaortic Stenosis to Nitroglycerin and to the Valsalva Maneuver. Circulation, 1964, 29, 422-431.	1.6	131
346	Diagnostic Value of the First and Second Derivatives of the Arterial Pressure Pulse in Aortic Valve Disease and in Hypertrophic Subaortic Stenosis. Circulation, 1964, 30, 90-100.	1.6	40
347	The Study of Left Ventricular Function in Man by Increasing Resistance to Ventricular Ejection with Angiotensin. Circulation, 1964, 29, 739-749.	1.6	292
348	Studies on Starling's Law of the Heart. Circulation, 1964, 30, 719-727.	1.6	103
349	Effects of Beta Adrenergic Blockade on the Circulation, with Particular Reference to Observations in Patients with Hypertrophic Subaortic Stenosis. Circulation, 1964, 29, 84-98.	1.6	219
350	Studies on Cardiac Dimensions in Intact, Unanesthetized Man. Circulation, 1964, 29, 186-194.	1.6	49
351	Idiopathic Hypertrophic Subaortic Stenosis: II. Operative Treatment and the Results of Pre- and Postoperative Hemodynamic Evaluations. Circulation, 1964, 29, .	1.6	52
352	Idiopathic Hypertrophic Subaortic Stenosis: I. A Description of the Disease Based Upon an Analysis of 64 Patients. Circulation, 1964, 29, SUPPL 4:3-119.	1.6	365
353	Idiopathic myocardial hypertrophy without congestive heart failure or obstruction to blood flow. American Journal of Medicine, 1963, 35, 7-19.	0.6	89
354	Interatrial Communication and Left Atrial Hypertension. Circulation, 1963, 28, 853-860.	1.6	53
355	Studies on the Function of the Adrenergic Nerve Endings in the Heart. Circulation, 1963, 28, 958-969.	1.6	52
356	Study of the Relationship Between the Neurotransmitter Store and Adrenergic Nerve Block Induced by Reserpine and Guanethidine. Circulation Research, 1963, 12, 264-268.	2.0	80
357	The Syndrome of Severe Mitral Regurgitation with Normal Left Atrial Pressure. Circulation, 1963, 27, 29-35.	1.6	181
358	Uptake and Metabolism of Tritiated Norepinephrine in the Isolated Canine Heart. Circulation Research, 1963, 12, 220-227.	2.0	29
359	Relationships Between the Release and Tissue Depletion of Norepinephrine from the Heart by Guanethidine and Reserpine. Circulation Research, 1963, 12, 256-263.	2.0	37
360	Starling's law of the heart. VII: Ventricular function in closed-chest unanesthetized dogs. American Journal of Physiology, 1963, 204, 439-445.	5.0	17

#	ARTICLE	IF	CITATIONS
361	Congenital Aortopulmonary Septal Defect. <i>Circulation</i> , 1962, 25, 463-476.	1.6	57
362	Determination of Fraction of Left Ventricular Volume Ejected per Beat and of Ventricular End-Diastolic and Residual Volumes. <i>Circulation</i> , 1962, 25, 674-685.	1.6	138
363	Transseptal Left Heart Catheterization. <i>Circulation</i> , 1962, 25, 15-21.	1.6	263
364	Hemodynamic-Phonocardiographic Correlations of the Fourth Heart Sound in Aortic Stenosis. <i>Circulation</i> , 1962, 26, 92-98.	1.6	52
365	The Effects of Surgical Abolition of Left-to-Right Shunts on the Pulmonary Vascular Dynamics of Patients with Pulmonary Hypertension. <i>Circulation</i> , 1962, 26, 1270-1278.	1.6	50
366	Analysis of the Acute Circulatory Effects of Guanethidine and Bretylium. <i>Circulation Research</i> , 1962, 10, 83-88.	2.0	27
367	Editorial. <i>Circulation</i> , 1962, 26, 161-165.	1.6	67
368	Augmentation of the Plasma Nor-Epinephrine Response to Exercise in Patients with Congestive Heart Failure. <i>New England Journal of Medicine</i> , 1962, 267, 650-654.	13.9	440
369	Studies on Digitalis. <i>Circulation</i> , 1962, 26, 166-173.	1.6	108
370	Studies on Starling's Law of the Heart. <i>Circulation</i> , 1962, 26, 516-524.	1.6	39
371	Effects of Reserpine and Guanethidine on Venous Reflexes. <i>Circulation Research</i> , 1962, 11, 889-894.	2.0	25
372	Circulatory effects of profound hypothermia during extracorporeal circulation. <i>American Journal of Physiology</i> , 1962, 202, 523-526.	5.0	11
373	STUDIES ON THE FIRST DERIVATIVE OF THE VENTRICULAR PRESSURE PULSE IN MAN. <i>Journal of Clinical Investigation</i> , 1962, 41, 80-91.	3.9	379
374	Studies on Starling's Law of the Heart. <i>Circulation</i> , 1961, 24, 633-642.	1.6	429
375	Precordial Scanning. <i>Circulation</i> , 1961, 23, 21-29.	1.6	21
376	A Hemodynamic Technic for the Detection of Hypertrophic Subaortic Stenosis. <i>Circulation</i> , 1961, 23, 189-194.	1.6	235
377	A Simplified Technic for the Detection of Patent Ductus Arteriosus and of Other Left-to-Right Shunts Originating from the Aorta. <i>Circulation</i> , 1961, 23, 279-285.	1.6	12
378	Studies on Digitalis. <i>Circulation</i> , 1961, 23, 376-382.	1.6	64

#	ARTICLE	IF	CITATIONS
379	Use of Krypton <sup>85</sup> for the Measurement of Cardiac Output by the Single-Injection Indicator-Dilution Technique. <i>Circulation Research</i> , 1961, 9, 984-988.	2.0	4
380	Influence of Carotid Baroreceptors and Vasoactive Drugs on Systemic Vascular Volume and Venous Distensibility. <i>Circulation Research</i> , 1961, 9, 75-82.	2.0	56
381	Left Atrial and Left Ventricular Pressures in Subjects without Cardiovascular Disease. <i>Circulation</i> , 1961, 24, 267-269.	1.6	163
382	Studies on Starling's Law of the Heart. <i>Circulation Research</i> , 1960, 8, 1254-1263.	2.0	88
383	Left Heart Catheterization by the Transseptal Route. <i>Circulation</i> , 1960, 22, 927-934.	1.6	119
384	Intracardiac Injection of Radioactive Krypton. <i>Circulation</i> , 1960, 21, 1126-1133.	1.6	32
385	A new technic for left ventricular angiocardiography and transseptal left heart catheterization. <i>American Journal of Cardiology</i> , 1960, 6, 1062-1064.	0.7	217
386	Functional Aortic Stenosis. <i>Circulation</i> , 1959, 20, 181-189.	1.6	181
387	Detection of Pulmonic and Tricuspid Valvular Regurgitation by Means of Indicator Solutions. <i>Circulation</i> , 1959, 20, 561-568.	1.6	36
388	Supravalvular Aortic Stenosis. <i>Circulation</i> , 1959, 20, 1003-1010.	1.6	113
389	A Simplified Indicator-Dilution Technic for the Localization of Left-to-Right Circulatory Shunts. <i>Circulation</i> , 1959, 20, 875-880.	1.6	26
390	Transseptal left atrial puncture. <i>American Journal of Cardiology</i> , 1959, 3, 653-655.	0.7	244
391	Origin of Heart Sounds as Elucidated by Analysis of the Sequence of Cardiodynamic Events. <i>Circulation</i> , 1958, 18, 971-974.	1.6	30
392	Congenital Aortic Stenosis. <i>Circulation</i> , 1958, 18, 1091-1104.	1.6	46
393	A Method for the Detection and Estimation of Aortic Regurgitant Flow in Man. <i>Circulation</i> , 1958, 17, 505-511.	1.6	57
394	Pulsus Alternans in Aortic Stenosis. <i>Circulation</i> , 1958, 18, 64-70.	1.6	33
395	The Nitrous Oxide Test. <i>Circulation</i> , 1958, 17, 284-291.	1.6	51
396	Left Atrial Pressure Pulse in Mitral Valve Disease. <i>Circulation</i> , 1957, 16, 399-405.	1.6	87

#	ARTICLE	IF	CITATIONS
397	Left Heart Catheterization by the Transbronchial Route. <i>Circulation</i> , 1957, 16, 1033-1039.	1.6	71
398	The Haemodynamic Effects of Circulatory Drugs in Patients with Idiopathic Hypertrophic Subaortic Stenosis. <i>Novartis Foundation Symposium</i> , 0, , 172-188.	1.2	1
399	Operative Treatment in Idiopathic Hypertrophic Subaortic Stenosis: Surgical Methods and the Results of Operation. <i>Novartis Foundation Symposium</i> , 0, , 250-265.	1.2	0
400	Cardiac xenotransplantation: a new path for the treatment of advanced heart failure?. <i>European Heart Journal</i> , 0, , .	1.0	1
401	Control of residual dyslipidaemic risk. <i>European Heart Journal</i> , 0, , .	1.0	4